GHRP-6
Growth hormone releasing hexapeptide — ghrelin receptor agonist
The original growth hormone secretagogue, and the reason ghrelin was discovered. It releases growth hormone and hunger in roughly equal measure, with no demonstrated body-composition benefit.
- Category
- Growth & Performance
- Half-life
- Roughly 15 to 60 minutes in reported summaries
- Cycle length
- Not established for repeated use
- Level
- intermediate
Overview
GHRP-6 is a synthetic hexapeptide discovered in the 1980s, and it is historically significant: its existence revealed a receptor that nobody knew existed and eventually led to the identification of ghrelin, the hormone that regulates hunger. Almost everything in the growth hormone secretagogue category descends from that discovery. In practice it is used for the same reason as GHRP-2 — a growth hormone pulse on demand — but its appetite-stimulating effect is far more pronounced, which makes it popular with people who struggle to eat enough and unhelpful for everyone else.
How it works
GHRP-6 was the first growth hormone secretagogue discovered, and it works by activating the receptor now known to be the ghrelin receptor, GHS-R1a. Activation causes growth hormone release from the pituitary and amplifies GHRH signalling. The same receptor is central to hunger signalling, which explains why appetite increases markedly after dosing, and modest elevations in cortisol and prolactin follow.
Reported benefits
- Large growth hormone release in human studies
- Powerful appetite stimulation through ghrelin signalling
- Historically important in understanding how growth hormone secretion is regulated
- Effects appear within minutes of injection
Reported benefits describe what the published literature and user reports suggest — not a promise of outcome for any individual.
Dosing reference
Research and community protocols describe 100 to 300 mcg per dose, two or three times daily. No dose-finding studies in healthy adults support those figures, and repeated dosing causes receptor desensitisation.
The appetite effect is the defining feature and the reason GHRP-6 is often taken during bulking phases. It is also the reason it is a poor choice for anyone trying to control food intake, and why dose escalation tends to deliver more side effects rather than more growth hormone.
Community-reported: 100–200 mcg two to three times daily, often timed shortly before meals, frequently stacked with a GHRH analogue before sleep.
These figures are what people report using in public communities. They have not been studied, verified or checked against certificates of analysis, and they are not a recommendation, a prescription or a target to aim for.
Where the reported amounts come from
Amounts are reproduced for education only. Doses from trials cannot be assumed to suit anyone else, and community-reported amounts are frequently wrong. Self-administering unapproved compounds carries serious risk.
The research picture
Human data on GHRP-6 is mostly pharmacological: it reliably raises growth hormone, stimulates appetite and causes modest increases in cortisol and prolactin. Its discovery underpinned the whole field of ghrelin research, including work that has since explored ghrelin signalling in appetite regulation and in conditions involving unintended weight loss. No controlled trial has shown that repeated GHRP-6 use improves body composition, strength or recovery in healthy people. The appetite effect is well documented, and anyone who gains weight while using it is not observing a novel anabolic effect — they are eating more.
Preclinical & non-clinical data
Like GHRP-2 it activates the ghrelin receptor, releasing growth hormone along with appetite-driven eating in animal studies; the hunger and cortisol effects are expected pharmacology rather than surprises.
Non-clinical data comes from cells and animals unless stated otherwise. It answers whether a compound is worth studying in people — not whether it is safe or effective in them.
What users report
This is the most appetite-focused reporting in the secretagogue category. Users describe near-immediate hunger that makes bulking targets easy and appetite control difficult, which is exactly why it persists in training communities despite being a poor fit for anyone trying to lose fat. Water retention, post-dose lethargy and a strong sense of cortisol-type stress responses are the complaints that repeat, and users say the hunger effect fades with frequent daily dosing.
Where these reports come from
These are unverified personal accounts collected from public sources. They are not evidence of effectiveness or safety, they have not been independently checked, and they are not a recommendation to use anything described.
Possible side effects
- Intense hunger within minutes of dosing
- Flushing, warmth and tingling
- Headache
- Lightheadedness
- Desensitisation and reduced response with repeated use
Safety notes
Repeated use desensitises the ghrelin receptor, which is why dosing several times daily tends to become less effective rather than more. Growth hormone secretagogues are inappropriate in people with active cancer or pituitary disease. Cortisol and prolactin increases are small but real, and there is no long-term safety data.
Stacking
Commonly stacked with a GHRH analogue, and with appetite-focused bulking protocols. There is no controlled evidence for any combination.
Related compounds
CJC-1295
Modified GRF 1-29, CJC-1295 without DAC
Growth & Performance
A GHRH analogue built for a sharp, short pulse.
Kisspeptin-10
KISS1-derived decapeptide — GnRH pathway activator
Growth & Performance
The peptide that controls the pulse generator behind the reproductive axis.
Tesamorelin
GHRH(1-44) analogue — Egrifta
Growth & Performance
The GHRH analogue with an approval and a narrow indication.